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Abstract
Background: The 8-amino and 9-hydroxy substituents of antimalarial cinchona alkaloids have the
erythro orientation while their inactive 9-epimers are threo. From the X-ray structures a 90°
difference in torsion angle between the N1-H1 and C9-O12 bonds in the two series is believed to
be important. In order to kill the malaria parasite, alkaloids must cross the erythrocyte and parasite
membranes to accumulate in the acid digestive vacuole where they prevent detoxication of
haematin produced during haemoglobin breakdown.
Methods: Ionization constants, octanol/water distribution and haematin interaction are examined
for eight alkaloids to explain the influence of small structural differences on activity.
Results: Erythro isomers have a high distribution ratio of 55:1 from plasma to the erythrocyte
membrane, while for the more basic threo epimers this is only 4.5:1. This gives an increased transfer
rate of the erythro drugs into the erythrocyte and thence into the parasite vacuole where their
favourable conformation allows interaction with haematin, inhibiting its dimerization strongly (90
± 7%) and thereby killing the parasite. The threo compounds not only enter more slowly but are
then severely restricted from binding to haematin by the gauche alignment of their N1-H1 and C9-
O12 bonds. Confirmatory molecular models allowed measurement of angles and bond lengths and
computation of the electronic spectrum of a quinine-haematin complex.
Conclusion: Differences in the antiplasmodial activity of the erythro and threo cinchona alkaloids
may therefore be attributed to the cumulative effects of lipid/aqueous distribution ratio and drug-
haematin interaction. Possible insights into the mechanism of chloroquine-resistance are discussed.
Background
Aryl amino alcohol alkaloids from the bark of Cinchona
spp. have played an invaluable role in the treatment of
malaria since the 18th century when the extract became
widely used. The bark contains laevorotatory (-) quinine
(6'-methoxy cinchonan-9-ol) (Q), its diastereomer dex-
trorotatory (+) quinidine (QD), and their 9-epimers
epiquinine (EQ) and epiquinidine (EQD). Also present
are (-) cinchonidine (des methoxyquinine) (CD), its dias-
tereomer (+) cinchonine (C) and their 9-epimers
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epicinchonidine (ECD) and epicinchonine (EC). With the
purification of Q as the major alkaloid, it remains the
main therapeutic drug for severe and complicated Plasmo-
dium falciparum malaria [1]. In addition to the above alka-
loids, all of which contain the exocyclic unsaturated vinyl
group attached to C3 of the quinuclidine ring, Cinchona
bark produces the analogous dihydro compounds of
which hydroquinine (HQ) and its diastereomer hydro-
quinidine (HQD) are examples, in which the exocyclic
double-bond has been reduced to the saturated ethyl
group (figure 1).
Q and other aryl amino alcohols competitively inhibit [2]
morphological changes caused by chloroquine (CQ) [3,6]
in digestive vacuoles (lysosomes) of the erythrocytic para-
site where haemoglobin is digested. All these agents
become concentrated in infected erythrocytes [4], and, as
weak membrane-soluble bases, are believed to accumu-
late in the acidic digestive vacuole contents where they
undergo protonation [5]. They are thought to cause the
death of the intraerythrocytic malaria parasite by binding
to toxic haematin [6,7] released during haemoglobin
digestion, preventing its dimerization to non-toxic
malaria pigment (haemozoin, β-haematin [8]).
In chemical structure, cinchona alkaloids consist of a con-
jugated heterocyclic quinoline ring, joined to a bulky rigid
bicyclo heterocyclic aliphatic quinuclidine ring by an
alcoholic carbon, C9. This is one of four chiral centres in
these molecules; only C8 and C9 vary in configuration,
while C3 and C4 on the aliphatic ring (respectively rectus,
R and sinister, S), are erythro and invariant. Centres C8
Cinchona alkaloids: structures to illustrate the stereochemistry Figure 1
Cinchona alkaloids: structures to illustrate the stereochemistry. Q = quinine, QD = quinidine, EQ = epiquinine, EQD = epiqui-
nidine, HQ = hydroquinine, HQD = hydroquinidine, CD = cinchonidine, C = cinchonine, ECD = epicinchonidine, EC = 
epicinchonine.
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and C9 are S and R in Q and R and S in QD, both erythro.
Their 9-epimers are 8S and 9S in EQ and 8R and 9R in
EQD, both threo. (figure 1) In 1938 it was reported from
the Wellcome Laboratories of Tropical Medicine, London,
that EQ and EQD had little activity against experimental
avian malaria [9]. Further, a clinical study found in 1948
that while Q and QD effectively treated induced P. falci-
parum infections, QD was twice as potent as Q [10]. Un-
natural (8R,9S,3S,4R) HQ and (8S,9R,3S,4R) HQD syn-
thesized at Hoffmann la Roche by Brossi's group were
each as active in P. berghei infections in mice as natural
HQ and HQD [24].
Before P. falciparum cultures [11] were available, EQ was
confirmed inactive in short-term cultures of P. berghei. In
agreement with the earlier clinical study, QD was four
times more active than Q, and C three times more active
than CD, emphasising the antiparasitic superiority of the
dextrorotatory (+) alkaloids of the QD type [2].
In the synthetic aryl amino alcohols, however, erythro
(1SR, 2RS)-mefloquine (WR 142,490) was only 2.5 times
more active than the threo  (1RS, 2RS)- racemate WR
177,602, and erythro WR 122,455 was 0.7 times as active
as its threo racemate WR 165,355. This small difference in
relative activities of erythro and threo mefloquine and WR
122,455, compared with the lack of activity of the threo
epimers of the cinchona alkaloids, was attributed to the
ease of rotation of the less bulky piperidine ring, which
replaces the quinuclidine ring in these synthetic agents,
around the link between the two relevant asymmetric car-
bon atoms (C-8 and C-9 in the cinchona alkaloids). As a
result of these studies a drug receptor was proposed, com-
prising 2 planar areas accommodating the quinoline rings
of Q and QD with, in between, an electropositive area in
the plane and a raised electronegative area [2]. The recep-
tor concept was refined in 1981 on the basis of an experi-
mental study of haematin interactions with aryl amino
alcohol antimalarial drugs, and evidence for a co-ordina-
tion link between such drugs and haematin iron was
obtained [12].
In 1990, using cultures of CQ-sensitive P. falciparum,
Wesche & Black confirmed higher activity of (+)QD than
(-) Q, and of (+) C than (-) CD [13]. In addition, Karle et
al. [14] found that, like (+) QD vs. (-) Q, (+) mefloquine
was slightly more effective than (-) mefloquine against P.
falciparum in vitro but this difference did not apply to
enantiomers of aryl amino alcohols whose side-chains
were more flexible than piperidine. They found in a fur-
ther study that EQ and EQD were approximately 100
times less active than quinine and quinidine against chlo-
roquine-sensitive  P. falciparum in vitro while HQ and
HQD were about 25% more active than Q and QD against
CQ-sensitive P. falciparum in vitro [15].
One explanation for the much lower activity of EQ and
EQD had been the suggested potential for intramolecular
H-bonding between aliphatic N-1 and adjacent O-12
because of the shorter distance between these atoms [16],
thereby reducing the ability of the drug to interact with a
putative cellular receptor site. Crystallographic evaluation
by Karle et al. revealed that the N-1 to O-12 distances in
the epimers were similar to those of other active amino-
alcohol antimalarials, and all showed potential for form-
ing H-bonds with cellular constituents. However, the tor-
sion angle between the N1-H1 and C9-O12 bonds
showed a 90° difference between the erythro- and threo-
alkaloids. These authors concluded that the main reason
for the inactivity of EQ and EQD was that threo-alkaloids
could not form intermolecular H-bonds with cellular
receptor sites in the same direction as the active erythro-
isomers [15]. Recently Karle & Karle have compared the
crystal structures of Q and QD with those of (-) and (+)
mefloquine to derive a pharmacophore which defines the
main features of the parasite's receptor [17].
Their findings are of considerable interest with respect to
the proposed receptor for these drugs, haematin, which
has a large planar area containing 4 N atoms co-ordinated
with FeIII. The Q-haematin complex is formed by hydro-
phobic interaction between the conjugated rings and co-
ordination between FeIII and the hydroxyl group on C-9 of
Q [18]. In water, solid haemin chloride (monomeric hae-
matin) will readily dissolve in solutions of the antimalar-
ially active erythro alkaloids Q, QD, CD and C to form
benzene-soluble co-ordination complexes with α- and β-
hemichrome absorption peaks around 600 and 490 nm.
This does not occur with the inactive EQ [12]. More
recently, it has been shown that Q, but not EQ, inhibits
spontaneous haematin dimerization to β-haematin  in
vitro [19].
We report below that haematin dimerization is also not
inhibited by EQD and confirm the lack of activity of EQ
and the activity of Q, QD, HQ, HQD, C and CD in this
model system. We have also obtained reliable values for
the octanol/water partition coefficients (Log P) and ioni-
zation constants (pKa values) of Q, QD, HQ, HQD, EQ,
EQD, C and CD. This enables us to predict the log distri-
bution ratio between water and lipid (logD) both at the
physiological pH and at the acidic pH of the parasite lys-
osome, where haematin is released from haemoglobin,
and to calculate the possible intralysosomal concentra-
tion ratios that would be expected, assuming the drugs are
concentrated by hydrogen ion. These observations are dis-
cussed in the context of molecular modelling, in order to
evaluate physicochemical and structural determinants of
drug activity against chloroquine-sensitive and resistant P.
falciparum. Our conclusions throw light on the prerequi-
sites for activity in cinchona alkaloids, the nature of theMalaria Journal 2003, 2 http://www.malariajournal.com/content/2/1/26
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haematin-quinine interaction, and the mechanism of
chloroquine-resistance.
Methods
Physicochemical data
The accumulation of an ionizable drug in cells is deter-
mined (apart from special transport mechanisms) by two
major parameters: the partition coefficient P between the
aqueous and the lipid phase, usually expressed as log P
(measured in the octanol-water system for the un-ionized
compound), and its modification by the ionization con-
stant(s) (pKa) of the drug. For partially ionized com-
pounds, the partition coefficient between 2 phases at any
fixed pH is called the distribution coefficient D, usually
expressed as log D; this assumes that only the un-ionized
species partitions from the aqueous to the organic phase
[20]. The difference between log P and log D is, therefore,
determined by the percentage of the drug ionized at differ-
ent pH values and is given by the standard equation for a
base [21]. When the difference between pKa and pH is
more than 1.0 log unit, it has been shown [22] that one
can merely subtract this difference from log P to obtain
log D. This makes it possible to calculate log D [23] from
a knowledge of log P, pKa and pH. The availability of the
ClogP programme, developed by C. Hansch and A. Leo at
Pomona College, California, as part of the Pomona Col-
lege Medicinal Chemistry Project, has now provided a
useful method of computing approximate log P values for
compounds of known structure. Values may sometimes
be unreliable since differences due to conformational
isomerism are not detected [25].
In the case of a drug possessing two basic centres, as qui-
noline antimalarial drugs all do, the correction needed in
log P to obtain log D at a given pH involves the additive
contribution of both ionized species, and the base equa-
tion [21] must be modified: [26,28].
Equation (1) for a diacidic base
Log D at the physiological pH of 7.4 was obtained exper-
imentally from the plot of log D versus pH. This was com-
pared with the calculated value of Log D, obtained from
Log P, using equation (1). Log D at the probable pH of the
digestive vacuole or lysosome was calculated from log P
by substituting pH 5.2 [27] for 7.4 in equation (1). The
application of equation (1) provides a useful rapid
method of checking measured values of log D, and of cal-
culating these values from log P when unknown. It should
be noted that for diacidic bases, pKa1 > pKa2.
Vacuolar accumulation ratios
To calculate the vacuolar accumulation ratios (VAR) that
weakly basic lipophilic drugs might achieve by virtue of
the pH difference between lysosome and external
medium or plasma [5], the equation of Henderson & Has-
selbach was used in the following form [29].
Equation 2
Dissociation constants and partition coefficients were
determined by Robertson Microlit Laboratories (Madison,
New Jersey, USA) at 25°C using the Sirius GLpK auto-
mated computerized potentiometric system [30]. Titra-
tion employed water containing 0.15 N KCl in an argon
atmosphere. The pKas were determined in triplicate with a
S.E. of ± 0.20.
Partition coefficients between octan-1-ol and water were
measured by dual-phase potentiometric titration using
various amounts of water-saturated octanol. Titrant addi-
tion was carried out with vigorous stirring of the assay
solution. Three different ratios of octanol/water were
employed for each compound. The log P values were
obtained from the difference between the aqueous pKa of
the species and the apparent pKa determined from the
dual phase titration [31]. Measurements were carried out
in triplicate with a S.E. of ± 0.40. The potentiometric
method was validated by comparison with results
obtained by the standard shake-flask technique [32].
The drug lipophilicity values at pH 7.4 and 5.2 (log D) are
the octanol/water distribution ratios, and were obtained
from the plot of log P versus pH. Calculated log D values
for pH 5.2, representing the conditions in the lysosome,
and for log D at pH 7.4, were obtained using equation (1).
β-Haematin Inhibitory Activity: BHIA
The method was slightly modified from Parapini et al.
[33]. The 8 M sodium acetate/acetic acid buffer (pH 5.0)
was prepared as follows:
Make up solid sodium acetate to 8 M with warm water
(continue to heat at 37°C in a water bath while mixing: it
will not dissolve completely) and then adjust the pH to
5.0 with 8 M acetic acid at 37°C, which leads to the
remaining solid dissolving).
One hundred µL was dispensed into wells of a microtitre
plate, and 50 µL of alkaloid hydrochloride or sulphate
solution in water, at 80 mM, or water alone, was added.
Verapamil (VE) and promethazine (PMZ) (Sigma Chemi-
cals, Poole, UK) were used as hydrochlorides. CQ (Sigma,
UK) was used as the diphosphate. Addition of 50 µL of an
log log log[ ] () ( ) DP pK pH pK pK pH a1 a1 a2 =−+ + −+ − 11 0 1 0 2
[] / [ ] / () ( ) Drug Drug vac outside
pK pH pK pK 2pH a1 v a1 a2 v =+ + −+ − 11 0 1 0 1 11 0 1 0 2 ++ −+ − () ( ) . pK pH pK pK pH a1 0 a1 a2 0Malaria Journal 2003, 2 http://www.malariajournal.com/content/2/1/26
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8 mM α-chlorohemin (Sigma, UK) solution in DMSO to
each well started the experiment.
Experiments were allowed to run at 35°C for 24 hr., done
in triplicate and repeated on three occasions. The final
DMSO concentration in this system was 25% w/v, while
final haematin concentration (0.4 µmol/well) was 2 mM,
and the final drug concentration (4.0 µmol/well) was 20
mM. Drug/haematin molar ratio was 10:1.
Then insoluble β-haematin and haematin aggregate were
pelleted by centrifugation at 3000 g for 20 min at room
temperature (22°C) and the supernatant discarded. Two
hundred µL of DMSO were added to each pellet to dis-
solve un-reacted haematin and centrifugation was
repeated. After discarding the supernatant, 200 µL of 0.2
M NaOH were added to convert the β-haematin pellet to
soluble alkaline haematin. For each well the alkaline hae-
matin was quantified by serial twofold dilution in water
and OD measurement at 414 nm. The effect of each agent
on β-haematin production was recorded compared with
the control (water + DMSO + acetate buffer alone).
Molecular modelling
Each mono-protonated cinchona alkaloid structure was
built in HyperChem Release 7 for Windows (Hypercube
Inc. Gainesville, Florida) using a molecular mechanics
procedure under MM+ [34] with bond-length restraints
for N1-O12 and N1 to C5' distance [15] (bond dipoles,
no cut offs employed). The geometry was optimised to an
rms (root mean square) gradient of 0.001 in vacuo
(Polak-Ribière method). A periodic box, 15 × 15 × 15Å
around the drug was then set up, containing 112 water
molecules. The system was optimised in MM+ using
switched cut-offs (outer 7.5 and inner 3.5 Å), to an rms
gradient of 0.5. Then a molecular dynamics programme
was run for 1 ps, with 0.001 ps steps, relaxation time 0.1
ps, to a simulation temperature of 300 K. This was fol-
lowed by MM+ geometry optimisation to an rms gradient
of 0.2. The molecular dynamics run was repeated and a
further MM+ protocol was carried out to a gradient of rms
0.004 on the selected drug.
Angles and bond-lengths were measured on the models,
and the dipole moments were determined after removal
of the N-1 proton, using the semi-empirical PM3 pro-
gramme [35,36] in singly-excited configuration interac-
Table 1: Physicochemical parameters of Cinchona alkaloids. cpd. = compound, VAR = calculated vacuolar accumulation ratio. S = 
chloroquine-sensitive, R = chloroquine-resistant. S/R = ratio of IC50 values. BHIA = % inhibition in β-haematin inhibition test
Cpd. pKa1 pKa2 Log P Log D (pH7.4) Log D (pH5.2) VAR IC50 nM S IC50 nM R RATIO S/R BHIA % inhib.
Q 8.58a 4.12b 3.17c 1.97e 0.30 161.0 29.315 103.215 0.28 84 ± 1
2.79d 1.96f -0.25f
QD 8.58g 4.42h 2.84i 1.66j 0.40k 173.2 13.415 43.715 0.31 85 ± 9
2.79d 1.63f -0.61f
HQ 9.01 l 4.29 3.07 1.50 0.53 173.6 21.315 151.715 0.14 93 ± 0.6
3.27d 1.45f -0.79f
HQD 9.16 4.34 3.43 1.72 0.75 177.5 10.415 74.115 0.14 95 ± 0.4
3.27d 1.66f -0.59f
C 8.35m 4.28n 2.82o 1.85p -0.38f 159.6 18.346 70.846 0.26 94 ± 0.5
2.49d 1.82f
CD 8.40q 4.17r 2.68s 1.73t -0.56f 157.5 69.546 206.846 0.34 94 ± 0.4
2.49d 1.64f
EQ 9.54u 4.08 2.90 0.76 -1.44 169.2 347115 117915 2.94 2 ± 13
2.79d 0.76f -1.47f
EQD 9.39v 4.15 2.53 0.55 -1.2 170.8 270015 102415 2.64 12 ± 12
2.79d 0.54f -1.70f
CQ 10.18 8.38 4.72 0.96 -3.44 22750 18.5 264 0.07 81 ± 15
0.92f -3.44f
VE 8.462 <0 3.7962 2.75f 0.59f 144.2 720053 250053 2.88 0 ± 21
PMZ 9.1142 <0 4.7542 3.03f 0.84f 155.5 143652 83552 1.70 15 ± 22.5
a: Lit 8.43[64], 8.4[39], 8.05[65], 8.59[66]. In 80% methylcellosolve/20% water 7.73[41], 7.25[67] ; b: Lit. 4.34[64],4.32 [39], 4.33 [66]. In 80% 
methylcellosolve 2.81[67], 2.38[68] ; c: Lit. 3.44[22], 2.64[65] ; d: Calc. from CLogP ; e: Lit. 1.90[65], 2.14[22], 2.54[69], 1.73(pH7.0)[70] ; f: Calc 
from eqn. (1). ; g: Lit. 8.79[64], 7.95[41], 8.78[42]. In 80% methylcellosolve 7.95[41]7.36[67] ; h: Lit. 4.34[64], in 80% methylcellosolve 2.66[67], 
2.40[68] ; i: Lit: 2.88[65], 3.71[42] ; j: Lit. 2.03[72], 2.07[74],2.11[31], 2.22[65]; k: Lit: -0.07[42] ; l: Lit. 8.87[40] ; m: Lit. 8.35[40], 8.32[65]. In 80% 
methylcellosolve 7.36[68] ; n: Lit. 4.28[67], In 80% methylcellosolve 2.80[67], 2.15[68] ; o: Lit 2.82[65]; p: Lit 1.85[65] ; q: Lit. 8.40[40], 8.30[65]; r: 
Lit. 4.17[40]. In 80% methylcellosolve 2.66[67], 2.12[68] ; s: Lit. 2.68[65] ; t: Lit. 1.73[65] ; u: Lit. In 80% methylcellosolve 8.44[41] ; v: Lit. in 80% 
methylcellosolve 8.32[41].Malaria Journal 2003, 2 http://www.malariajournal.com/content/2/1/26
Page 6 of 14
(page number not for citation purposes)
tion. (RHF [Restricted Hartree-Fock], charge 0, spin
multiplicity 1, lowest state, orbital criterion, five occupied
and five unoccupied orbitals.)
Models of the Q-haematin and EQ-haematin complexes
were prepared in MM+ using the structures of Q and EQ
optimised in water (see above), with a co-ordination link
between haematin iron and drug O-12. The crystal struc-
ture of α-chlorohaemin [37] was used for the initial hae-
matin monomer model.
The semi-empirical quantum mechanics program
ZINDO/S [38] in singly excited configuration interaction
was used to calculate the expected electronic spectrum of
the optimised 1: 1 quinine/haematin complex in ben-
zene. One molecule of singly protonated quinine, co-
ordinated to one molecule of haematin, with carboxylic
acid groups undissociated, was given an arbitrary charge
of +1 and spin multiplicity of four. Fifteen occupied and
15 unoccupied orbitals were included in the calculation.
(EQ and EQD were kindly supplied by Dr. Reinecke of
Buchler GmbH, D-38110 Braunschweig, Germany.)
Results
Physicochemical
Q and QD, C and CD are reported to have very similar
pKa1 values (8.4 ± 0.4) for the quinuclidine aliphatic N
(table 1: footnotes). A value of 8.5 ± 0.15 (table 1) was
found, with a slight increase in HQ and HQD due to the
conversion of the electron-attracting vinyl group to an
ethyl group. All the cinchona alkaloids in table 1 had very
similar pKa2 values (4.25 ± 0.15) for the more weakly
basic quinoline aromatic N. The only previous determina-
tions [41] for the threo compounds EQ and EQD were
carried out in 80% methyl-cellosolve / 20% water and
showed both 9-epimers to have higher pKa values than Q
and QD in the same solvent. Results obtained in water
(Table 1) confirmed this finding and revealed a consistent
∆pKa1 of 1.1 units between the two solvent systems, and of
1pKa unit between the erythro and the threo isomers.
Experimental values for log P are shown in table 1 as are
the figures calculated using the ClogP programme. The
two sets are in generally good agreement, and show the
expected slight increase (+0.4) with the dihydro com-
pounds (HQ and HQD) and decrease (-0.3) with the loss
of the 6-methoxy group (C, CD). Experimental measure-
ment of log D vs pH over the range 3–11 permitted the
determination of log D at pH 7.4. In addition knowledge
of log P and pKa allowed the calculation of log D at pH 7.4
using equation (1). Measured and calculated figures
(table 1) are in good agreement, while reported values
(table 1: footnotes) show a wider variation. Results for log
D at pH 7.4 for the erythro compounds fall in the range
1.50–1.97 (mean 1.74 ± 0.24) while the threo isomers
(range 0.55–0.76) show a mean of 0.66 ± 0.11. In view of
the acidic milieu (pH 5.2) existing in the vacuole within
the lysosomal membrane, log D at pH 5.2 was also meas-
ured and calculated and the figures are shown in table 1.
The comparison of calculated results for these agents at
pH 5.2 with those obtained for chloroquine (CQ) is of
interest, since because of CQ's two high pKa  values
[43,44], the drop in pH had a much larger influence than
on Q, QD, EQ or EQD. The drop in log D between pH 7.4
and pH 5.2 for Q, QD, EQ and EQD was ~2 logs while for
CQ it was > 4 logs.
The parasite lysosome, which has been proposed as the
main site of drug uptake, has an acidic pH. Assuming drug
distribution reaches an equilibrium state, and only
uncharged drug can pass through membranes, it is argued
that the ratio between concentration of drug outside the
erythrocyte and the concentration in the lysosome
depends on the difference between [H+] of the medium in
vitro or plasma in vivo (pH 7.4), and the lysosomal com-
partment, according to the Henderson-Hasselbach equa-
tion [5]. Both the water/lipid partition (log P) and the
acid dissociation constant(s) (pKa) of a drug influence the
passage of drug into the lysosome and its trapping by pro-
tonation. Trapping of a drug in the acidic vacuole is
enhanced if the base, like chloroquine (CQ), can accept
more than one proton at the lysosomal pH [28]. Calcu-
lated CQ concentrations within the infected erythrocyte
approximate to measured uptake values, but the more
lipophilic agents like amodiaquine (AQ) achieve signifi-
cantly greater levels than calculated, indicating that other
factors are involved in the concentrative uptake of the
drug [29]. Calculated lysosomal uptake ratios (vacuolar
accumulation ratio: VAR, the ratio of calculated drug con-
centration in the lysosomal water to concentration in the
external medium water at equilibrium) for cinchona alka-
loids, for resistance-reversers VE and PMZ, and for CQ are
given in table 1. The most interesting finding here was the
small variation in calculated VAR seen among the eight
alkaloids examined (mean: 167.8 ± 7.4 [SD]). The minor
variation reflects slight differences in the protonation of
the aromatic N at pH 5.2, while the aliphatic N is 100%
protonated in all the alkaloids examined.
BHIA test
A 10 fold molar excess of Q, QD, HQ, HQD, C, CD, or CQ
inhibited the BHIA haematin dimerization reaction. Sig-
nificant inhibition was not seen with EQ, EQD, VE or
PMZ. (Table 1, figure 2). These results fit in with the
reported high activity of CQ [73] and the erythro cinchona
alkaloids on P. falciparum and the low activity of EQ, EQD
[15,46], PMZ [52] and VE [53].Malaria Journal 2003, 2 http://www.malariajournal.com/content/2/1/26
Page 7 of 14
(page number not for citation purposes)
Molecular modelling (table 2)
As pointed out by Karle and co-workers, [15,46], the N1-
H1 bond in 8, 9 threo-alkaloids consistently points in the
same direction as the C9-O12 bond, while in the erythro-
alkaloids they are at right angles (see the last column of
table 2). The calculated dipole moment and proton affin-
ity of each active alkaloid are lower than that of its 9-
epimer, as first demonstrated by Karle & Bhattacharjee
[46]. This is confirmed by our finding of higher pKa1 val-
ues for the 9-epimers (table 1). Dipole moments and pro-
ton affinities calculated here consistently differ from
values in ref. [46], probably because we used a semi-
empirical configuration interaction calculation rather
than an ab initio approach.
Space-filling models of the cinchona alkaloids orientated
to face a putative receptor are shown in figure 3.
Q-haematin model
A Q-haematin co-ordinated model was calculated using
MM+, in comparison with EQ-haematin. The results of
the ZINDO/S calculation of the electronic absorption
spectrum of Q-haematin are compared with experimental
observations in table 3 below. Differences in the orienta-
tion of the N1 proton with respect to the quinoline and
porphyrin rings are shown in figure 4 below.
Discussion
The cinchona alkaloids have an aromatic N with a pKa of
4.25 ± 0.15. At pH 7.4 the aromatic N is 100% un-ionized
and makes its maximum contribution to lipophilicity. In
the active erythro alkaloids, with partial protonation of the
aliphatic N, this results in a log D at pH 7.4 of 1.74 ± 0.25
corresponding to a favourable mean membrane transfer
ratio into the lipid phase of 55:1. This is applicable to the
% β-haematin synthesis inhibition (BHIA) by cinchona alkaloids, chloroquine (CQ), verapamil (VE), promethazine (PMZ) and  water (Cont) Figure 2
% β-haematin synthesis inhibition (BHIA) by cinchona alkaloids, chloroquine (CQ), verapamil (VE), promethazine (PMZ) and 
water (Cont). Standard deviations are shown (n = 9).
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Table 2: Electronic and structural parameters of cinchona alkaloids in aqueous solvent, based on the common pharmacophores 
described for (-) mefloquine and quinine and (+) mefloquine and quinidine by Karle & Karle [17]. (*dipole moment calculated for free 
base).
drug in 
water
MM+ energy 
<0.004
dipole 
moment*
proton 
affinity
O12-N1 N1-C5' ring-O12 
torsion°
O12-N1 
torsion°
H8-C8-C9-H9 
dihedral°
H-N1-C9-
O12 torsion°
Kcal/mole Debye Kcal/mole Å Å
Q 11.9 1.88 208.85 3.14 4.1 157.8 -83.8 -82.6 -123.2
EQ 15.5 2.44 213.36 2.77 4.7 40.6 43.3 174.0 -5.9
QD 18.9 1.66 208.61 3.09 4.2 -161.1 78.2 74.7 104.4
EQD 12.8 2.21 213.84 2.82 4.7 -43.2 -49.1 -175.8 0.6
CD 11.1 1.15 209.38 3.21 4.2 144.9 -91.0 -86.8 -129.6
ECD 13.6 1.54 213.88 2.79 4.6 45.1 46.0 175.0 -5.9
C 10.9 0.96 209.78 3.19 4.1 -156.0 88.9 85.3 118.3
EC 13.5 1.27 213.75 2.85 4.7 -45.4 -50.2 -176.2 -2.5
HQ 10.4 2.08 209.39 3.20 4.1 156.1 -83.6 -82.8 -123.6
HQD 10.7 1.79 209.75 3.23 4.2 -152.7 89.5 88.8 118.6
Space-filling models of cinchona alkaloids optimised in solvent water Figure 3
Space-filling models of cinchona alkaloids optimised in solvent water. Each structure is orientated facing a putative receptor. N 
= dark blue, C = light blue, O = red, H = grey.
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transfer of drug from blood plasma water to erythrocyte
and subsequent membranes. For the (weakly active) threo
epimers, the higher pKa of the aliphatic N, which is now
100% ionized and does not contribute to transfer into the
lipid phase, reduces log D at pH 7.4 by one magnitude to
0.66 ± 0.1, corresponding to a decreased membrane trans-
fer ratio of only 4.5: 1. It is known that CQ and other 4-
aminoquinoline antimalarials need to reach a high con-
centration within the lysosome of the CQ-sensitive para-
site in order to inhibit dimerization of the enclosed
haematin [47], and this is also assumed to apply to cin-
chona alkaloids. The rise in pKa1 values observed for the
inactive 9-epi alkaloids will therefore lower the rate at
which that effective concentration is reached. The acidic
Table 3: 1:1 Quinine-haematin complex: Observed and calculated values of electronic absorption peaks and peak strengths. (* Peak 
strength normalised by taking γ peak strength as 1.0.)
α peak (nm) β peak (nm) γ peak (nm) α peak * strength β peak* strength γ peak* strength [Q] / [H]
observed 602 490 408 10 1.2 1 0.8
calculated 545.4 489.4 408.4 5.4 1.1 1 1
Ratio obs/calc 1.1 1.0 1.0 1.9 1.1 1 0.8
Views of Q-haematin and EQ-haematin models from the edge of the porphyrin ring to show comparative orientation (black  arrows) of the electric field of the alkaloid N-1 proton (H-1) Figure 4
Views of Q-haematin and EQ-haematin models from the edge of the porphyrin ring to show comparative orientation (black 
arrows) of the electric field of the alkaloid N-1 proton (H-1). The haematin iron atom (just visible) is coloured magenta.
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environment of the vacuole (pH 5.2) results in substantial
ionization (~40%) of the aromatic N of the cinchona
alkaloids, with enhanced water solubility as shown by the
marked drop in log D (table 1), so that all eight com-
pounds are trapped there, causing their concentration to
increase in the low pH milieu.
The absence of significant inhibition of β-haematin for-
mation by both 9-epi alkaloids tested strengthens the link
between 8, 9 erythro configuration in cinchona alkaloids
and antiplasmodial activity, and indicates that reaching a
high concentration in the lysosome, though necessary, is
not sufficient in itself to confer antiplasmodial activity.
Once a drug is in the lysosome, it must be able to interact
with haematin, or with other vital functions like the pro-
teolysis of haemoglobin [48], in order to exert a toxic
effect.
Reported molecular electronic properties [46] of Q and
QD and their epimers are in agreement with measured
pKa values here. In Q and QD the positive electric field of
the aliphatic N1 proton is directed towards the quinoline
ring, and the dipole moment of the drug (unprotonated)
is reported as 2.2 Debye or less, while in the 9-epimers EQ
and EQD the field is directed towards the solvent and the
dipole moment is higher. N1 in the erythro-alkaloids is in
a position to interact with equatorial protons of the quin-
oline ring (C5' is only ~4 Å away). In the models the bulky
quinuclidine group finds difficulty in rotating close to the
quinoline ring in the threo-alkaloids; the O-12 is
interposed, and the N1-C5' distance is up to 4.7 Å (table
2), see also [15,46]. The probable reason for the higher
proton affinity of the N1 and lower logD in the threo alka-
loids is that the quinoline ring has less influence on N1
because of these steric factors, which lead to higher values
of pKa (easier protonation) of N-1. This will also enhance
interaction (H-bonding) with solvent water in the threo
compounds.
The Q-haematin complex
Some features of the modelled drug-haematin complexes
are of interest. The Fe-O12 bond length is 1.846 Å in Q-
haematin and 1.842 Å in EQ-haematin which can be com-
pared with 1.847 Å for the O-Fe distance in the high-spin
co-ordination complex with a phenoxide [49]. The mini-
mum distance between the carbon atoms of the quinoline
ring in the drug, and those in the porphyrin ring was 3.1
Å in both models. This would allow Van der Waals inter-
actions between the conjugated rings for both Q-haema-
tin and EQ-haematin.
The H1-Fe distance in Q-haematin is 4.6 Å, while in EQ-
haematin it is 3.9 Å, Proximity of positive charges of N1
proton and iron in EQ-haematin, and the higher value of
the proton charge [46] might make co-ordination com-
plex formation more difficult than for Q-haematin. The
more solvated, more positive, epimer N-1 proton may
interfere with the initial hydrophobic interactions of the
quinoline and porphyrin rings, affecting co-ordination of
O-12 to haematin iron. The importance of solvent water
interaction with protonated N1 in inhibiting hydropho-
bic binding to haematin is suggested by the observation
that in 40% DMSO both Q and EQ interact similarly with
haematin [50]. The direction of the positive electric field
of protonated N1 determines the higher pKa and solvent
interaction and is likely to be, as suggested by Karle and
colleagues [15,48], the crucial difference between the
inactive and active cinchona alkaloids, since this differ-
ence in direction, shown in figure 4, alters both the
stereochemistry of interactions between Q or EQ and hae-
matin and increases the solvation and charge of N1-H1 in
EQ. These considerations are supported by the lesser effect
of the threo/erythro distinction on the activity of meflo-
quine congeners and phenanthrene methanols (WR
122,455) where the piperidine ring is more easily able to
rotate close to the quinoline ring.
The peak wavelengths and strengths of the calculated elec-
tronic absorption spectrum compare well with the
observed spectrum of the aqueous complex, extracted into
benzene, reported earlier [12] (table 3). Despite the fact
that, in view of the discrepancy in wavelength and
strength of the α-peak, the structure is not yet completely
correct, the α- and β-peaks support the formation of a
hydrophobic quinine-haematin co-ordination complex
while the strong γ-peak at 408 nm indicates haematin iron
in a high-spin state, as expected from the putative struc-
ture. This is similar to α-chlorohemin [37], where FeIII is
0.45 Å above the plane of the porphyrin ring. It appears
unlikely that the quinoline ring interacts with the other
side of the haematin ring structure, as has been proposed
for the quinoline ring of CQ [63] since a high spin co-
ordination complex could not then be formed.
In summary, positive correlations between antiplasmo-
dial activity and drug lipophilicity have been reported
[43,45,47] for a number of 4-aminoquinoline drugs
related to CQ and amodiaquine (although not for the cin-
chona alkaloids) as well as for some aminothiol [74] and
hydroxamate [75] chelators. In addition, a
proportionality between activity and inhibition of forma-
tion of β-haematin has been recognized for 4-aminoquin-
olines [76] and also for Q and QD [19], The present
report, however, suggests that the differences in the
antiplasmodial potency of the erythro and threo cinchona
alkaloids on CQ-sensitive isolates of P. falciparum may be
accounted for as the cumulative consequences of their log
D (pH7.4) and BHIA values. The availability of these two
critical parameters within this highly homogeneous group
of drugs (table 1) makes it possible to apply a simple testMalaria Journal 2003, 2 http://www.malariajournal.com/content/2/1/26
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of their sequential and combined effects: The ratio of the
mean log D (pH 7.4) for the erythro compounds (1.74 ±
0.24) to that of the threo compounds (0.66 ± 0.11) is 12:1.
The BHIA values for the 2 series are 90 ± 7% and 7 ± 4%,
with a similar ratio of 12.5:1. Since these effects are cumu-
lative, their combined result would raise the mean IC50
value for the threo series to 150 (ie 12 × 12.5) times that
of the erythro group. With an experimental mean IC50 of
the erythro alkaloids of 26.7 nM, the calculated reduction
of activity of the threo alkaloids leads to an expected mean
IC50 of (26.7 × 150) ie 4.0 µM, while the observed exper-
imental value is 3.1 ± 0.4 µM. Alternatively the enhance-
ment in activity of the erythro series would lead to an IC50
of 3085/150 ie 20.6 nM; the experimental mean for the 6
erythro compounds is 26.7 nM.
The agreement between the calculated and experimental
values of IC50 is noteworthy.
These observations may provide a useful platform for the
further investigation of antiplasmodial agents, particu-
larly in the climate of increased drug-resistance.
Lessons for the interpretation of CQ-resistance 
mechanisms
Our arguments so far have concentrated on the probable
role of hydrophobicity (logD) and inhibition of haematin
dimerization as the determinants of antiplasmodial activ-
ity among eight cinchona alkaloids. Clearly these factors
are also important in activity against CQ-resistant isolates.
However, a further parameter, interaction with the CQ-
resistance mechanism, must also be considered. Entry to
the cell, concentration in the acidic lysosomal vacuole,
LogD values at pH 7.4 and activity in CQ-resistance (log [IC50S/IC50R]) for 4-aminoquinolines and cinchona alkaloids Figure 5
LogD values at pH 7.4 and activity in CQ-resistance (log [IC50S/IC50R]) for 4-aminoquinolines and cinchona alkaloids. 4-ami-
noquinoline values from ref. [73].
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and interaction with haematin have all been postulated as
the site of the resistance mechanism. Arguments
[61,77,78] and evidence [51,79,85] for and against drug
efflux have not yet reached a consensus. Nevertheless, the
most important mutations associated with CQ-resistance
are in the genes coding for two intrinsic proteins in the
membrane of the lysosome [80,56] where quinoline
drugs are believed to be concentrated.
One of these, PGH-1, is a protein of the multidrug-resist-
ance type [81], where over-expression is associated with
resistance to highly hydrophobic drugs such as meflo-
quine, halofantrine and artemisinin [82–84]. The other, is
PfCRT, where a Lys76Thr mutation is 100% associated
with CQ-resistance in vitro[56]. In clinical studies, inabil-
ity to detect the mutant allele predicts treatment success
[57]. Replacement of the wild type pfcrt gene in sensitive
clones by the resistance-associated allele from strains of
Asian or South American origin confers CQ-resistance,
accompanied by reduced uptake of the drug, and the
acquisition of the characteristic chemosensitizing effect of
VE [58]. The detailed structure of the PfCRT protein is still
under investigation. In its topology the sequence resem-
bles the aqueous chloride channel of Salmonella typhimu-
rium and a range of other organisms [59], though 3 of the
4 specific ion-binding motifs are modified. Modelling
(work in progress) reveals that the side chain of residue 76
may project into an access pore leading from the lyso-
somal content. In the wild type (Lys76) this is positively
charged, which would attract anions and repel cations.
Mutated to neutral Thr76, cations would find access eas-
ier. PfCRT has recently been expressed efficiently in yeast
Pichia pastoris by Roepe's research group [60], and func-
tionally appears to be a membrane channel which, when
mutated, may mediate chloride-dependent, VE-inhibita-
ble drug transport. Thus PfCRT could indeed be an anion
channel, and by varying the entrance or exit of charge-bal-
ancing chloride anion may modulate lysosomal pH
[87,88]. This might affect the trapping of basic drugs [5],
or interfere with drug-haematin binding [86]. Doubt has
been cast [89] on the validity of pH determinations under-
lying the argument in refs 86–88. These pH effects are per-
haps rendered unlikely by the stereospecific interactions
of the physico-chemically similar diastereomers Q and
QD with mutated PfCRT [58,90]. It is more likely that CQ
itself passes through modified PfCRT, since the high drug
and proton concentration in the lysosome present a for-
midable pressure for efflux, given a suitable channel.
For 4-aminoquinolines, the positive correlation between
hydrophobicity and relative activity in CQ-resistant iso-
lates, where the more hydrophobic AQ and its metabolite
DAQ show significant activity [54] is an important find-
ing. This observation is paralleled by the CQ-sensitising
effect, on CQ-resistant isolates, of lipophilic weak bases
like VE and PM [52,53]. We are investigating a link
between polymorphism in PfCRT, resistance reversal by
VE, and the clinical efficacy of AQ (in press).
VE and PM show no significant interaction with the hae-
matin polymerisation process (table 1, figure 2) and they
have little intrinsic antiplasmodial action. Combining our
recent data on 4-aminoquinolines [73] and the erythro
cinchona alkaloids studied here there is a significant cor-
relation between hydrophobicity and log relative activity
in CQ-resistant parasites, extending the observations of
Bray et al.[54] (figure 5).
It has been proposed [61,73] that 4-aminoquinolines
which are more polar at lysosomal pH (such as CQ) are
more likely to pass through the mutated PfCRT channel
and escape from the lysosome into the parasite cytoplasm,
while those which are more hydrophobic (AQ and its
active metabolite DAQ) are likely to bind to the hydro-
phobic channel lining and stay inside. Their positive
charges repel the further access of 4-aminoquinoline to
the channel. The high hydrophobicity in acid of VE and
PMZ (see table 1) would allow them to bind in a mutated
PfCRT channel and their positive charge would prevent
efflux of CQ and related drugs. Molecular computations
on CQ-resistance reversing agents have indeed deter-
mined that their common features are hydrophobicity
and electronegativity (i.e. proton attraction) [55].
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